Kyverna Therapeutics Inc (KYTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||
| Net Income | -127,477 | -60,366 | -28,893 |
| Depreciation Amortization | 2,133 | 1,707 | 1,051 |
| Accounts payable and accrued liabilities | 736 | 4,083 | 677 |
| Other Working Capital | 7,857 | 3,424 | -10,327 |
| Other Operating Activity | 2,501 | -1,258 | 1,379 |
| Operating Cash Flow | $-114,250 | $-52,410 | $-36,113 |
| Cash Flows From Investing Activities | |||
| Change In Deposits | -158,697 | -8,164 | -13,329 |
| PPE Investments | -2,205 | -621 | -768 |
| Investing Cash Flow | $-160,902 | $-8,785 | $-14,097 |
| Cash Flows From Financing Activities | |||
| Debt Issued | N/A | 59,900 | 11,954 |
| Debt Repayment | -956 | -781 | -249 |
| Common Stock Issued | 341,430 | 645 | 175 |
| Other Financing Activity | -3,361 | -1,646 | 0 |
| Financing Cash Flow | $337,113 | $58,118 | $11,880 |
| Beginning Cash Position | 35,212 | 38,289 | 76,619 |
| End Cash Position | 97,173 | 35,212 | 38,289 |
| Net Cash Flow | $61,961 | $-3,077 | $-38,330 |
| Free Cash Flow | |||
| Operating Cash Flow | -114,250 | -52,410 | -36,113 |
| Capital Expenditure | -2,205 | -621 | -768 |
| Free Cash Flow | -116,455 | -53,031 | -36,881 |